ETFMG Treatments Testing and Advancements ETF (GERM)
GERM is a passive ETF by ETFMG tracking the investment results of the Prime Treatments, Testing and Advancements Index. GERM launched on Jun 17, 2020 and has a 0.68% expense ratio.
ETF Info
| ISIN | US26924G7631 |
|---|---|
| CUSIP | 26924G763 |
| Issuer | ETFMG |
| Inception Date | Jun 17, 2020 |
| Region | North America (U.S.) |
| Category | All Cap Equities |
| Leveraged | 1x |
| Index Tracked | Prime Treatments, Testing and Advancements Index |
| Asset Class | Equity |
Asset Class Size | Multi-Cap |
Asset Class Style | Blend |
Expense Ratio
GERM features an expense ratio of 0.68%, falling within the medium range.
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: GERM vs. SBIO
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in ETFMG Treatments Testing and Advancements ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | N/A | 21.24% |
| 1 month | N/A | 0.55% |
| 6 months | N/A | 11.47% |
| 1 year | N/A | 32.45% |
| 5 years (annualized) | N/A | 13.43% |
| 10 years (annualized) | N/A | 11.05% |
Monthly Returns
The table below presents the monthly returns of GERM, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00% | ||||||||||
| 2023 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||||||
| 2022 | 0.00% | 0.00% | 0.00% | 0.00% | |||||||||
| 2021 | 0.00% | 0.00% | 0.00% | 0.00% | |||||||||
| 2020 | 0.00% | 0.00% | |||||||||||
| 2017 | -7.06% | -7.60% | 76.92% | 114.99% | 76.43% | 59.49% | 10.06% | 60.01% | -25.95% | 5.95% | 58.44% | 12.08% | 2,155.13% |
| 2016 | 18.97% | 18.97% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of GERM is 7, indicating that it is in the bottom 7% of ETFs on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for ETFMG Treatments Testing and Advancements ETF (GERM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
ETFMG Treatments Testing and Advancements ETF provided a 0.00% dividend yield over the last twelve months, with an annual payout of $19.50 per share.
| Period | TTM | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Dividend | $19.50 | $0.24 | $0.14 | $0.10 | $0.29 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Monthly Dividends
The table displays the monthly dividend distributions for ETFMG Treatments Testing and Advancements ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | $0.06 | $0.09 | $19.30 | $19.45 | |||||||||
| 2023 | $0.09 | $0.06 | $0.04 | $0.05 | $0.24 | ||||||||
| 2022 | $0.05 | $0.06 | $0.03 | $0.14 | |||||||||
| 2021 | $0.06 | $0.04 | $0.00 | $0.10 | |||||||||
| 2020 | $0.29 | $0.29 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the ETFMG Treatments Testing and Advancements ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ETFMG Treatments Testing and Advancements ETF was 99.93%, occurring on Dec 14, 2016. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.93% | Dec 14, 2016 | 1 | Dec 14, 2016 | — | — | — |
| -0.81% | Dec 12, 2016 | 1 | Dec 12, 2016 | 1 | Dec 13, 2016 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.